1668-19-5
1668-19-5
Chemical Structure
Doxepin
- CAS No.: 1668-19-5
- Formula:C19H21NO
- Molecular Weight:279.38
IUPAC Name: (E)-3-(dibenzo[b,e]oxepin-11(6H)-ylidene)-N,N-dimethylpropan-1-amine
InChIKey: ODQWQRRAPPTVAG-GZTJUZNOSA-N
SMILES: CN(C)CC/C=C1C2=CC=CC=C2OCC3=CC=CC=C/13
Biological Activity: Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant. Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system. Doxepin has also been proposed as a protective factor against oxidative stress[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Doxepin | 99.66% | Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant. Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system. Doxepin has also been proposed as a protective factor against oxidative stress. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxepin-d3 | Doxepin-d3 is the deuterium labeled Doxepin (HY-B0725A). Doxepin s an orally active tricyclic antidepressant agent. Doxepin is a potent and selective histamine receptor H1 antagonist. Doxepin is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2. Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant. Doxepin has therapeutic effects in atopic dermatitis, chronic urticarial, can improve cognitive processes, protect central nervous system. Doxepin has also been proposed as a protective factor against oxidative stress. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. AnnemiekVermeeren, et al. Effects of the use of hypnotics on cognition. Progress in brain research vol. 190 (2011): 89-103. [Content Brief]
- [2]. G Hajak, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. The Journal of clinical psychiatry vol. 62,6 (2001): 453-63. [Content Brief]
- [3]. Mahsa Gharzi, et al. Effects of different doses of doxepin on passive avoidance learning in rats. Advanced biomedical research vol. 2 66. 30 Jul. 2013. [Content Brief]
Keywords
